Navigation Links
Schering-Plough Schedules Conference Call Webcast For 2009 Third Quarter Earnings
Date:10/12/2009

KENILWORTH, N.J., Oct. 12 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) is scheduled to announce its sales and earnings results for the 2009 third quarter on Thursday, Oct. 22, 2009.

At approximately 7:15 a.m. (EDT) on that day, Schering-Plough will conduct a conference call to review results for the 2009 third quarter. Fred Hassan, Schering-Plough's chairman and CEO, and other members of management will host the conference call.

To listen live to the call, dial 1-877-565-9664 or 1-706-634-5003 and enter conference ID # 33373738. A replay of the call will be available beginning later on Oct. 22 through 5 p.m. on Thursday, Oct. 29. To listen to the replay, dial 1-800-642-1687 or 1-706-645-9291 and enter the conference ID #33373738. A live audio webcast of the conference call also will be available by going to the Investor Relations section of the Schering-Plough corporate Web site, www.schering-plough.com, and clicking on the "Presentations/Webcasts" link. A replay of the webcast will be available starting on October 22 through 5 p.m. on November 2.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SOURCE Schering-Plough Corporation


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients
2. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
3. Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
4. Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
5. Schering-Plough Announces Results of the Early ACS Trial
6. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
7. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
8. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
9. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
10. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
11. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... India , February 22, 2017 According ... Product (Scissors, Forceps, Trocar, SIMS, CUSCO), Application (Laparoscopy, Colposcopy, Hysteroscopy, D&C, ... Global Forecast to 2021", published by MarketsandMarkets, the global market is ... Billion in 2016, at a CAGR of 7.1% during the forecast ... ...
(Date:2/22/2017)... DUBLIN , Feb 22, 2017 ... "Dermatology Therapeutics Drug Development Pipeline Review, 2016" report to ... ... types of disorders worldwide, and approximately one-third of the US ... the past decades, the majority of the dermatology market has ...
(Date:2/22/2017)... A research report by Arcview Market Research ... and the continuously changing landscape of the legal market reveals that ... North America , a 30% increase from 2015. According ... by the year 2021 representing a 26 percent compound annual growth ... and Canada is gradually becoming ...
Breaking Medicine Technology:
(Date:2/22/2017)... Jacksonville, Fla. (PRWEB) , ... February 22, 2017 ... ... aneurysms is just as effective on smaller and sometimes harder to reach ones, ... findings were presented at the International Stroke Conference in Houston by Ricardo A. ...
(Date:2/22/2017)... , ... February 22, 2017 ... ... of their newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp ... which provides instant absorption from the mouth into the bloodstream. Far ...
(Date:2/22/2017)... ... February 22, 2017 , ... ANGLESTRONG , the new recovery management ... on the App Store and Google Play . Florida-based Sober Network, ... and recovery industry, partnered with Angle to build ANGLESTRONG. The new recovery management app ...
(Date:2/22/2017)... ... February 22, 2017 , ... Bellus Medical, ... latest innovation in the delivery of Platelet Rich Plasma (PRP). PRP systems are ... management, to accelerate tissue synthesis and provide a faster and more efficient healing ...
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five ... of those report that family members or friends have also commented about their ... hearing loss wear hearing aids. One reason, suggested by 89 percent of American ...
Breaking Medicine News(10 mins):